(NASDAQ:TVRD), HOUSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Tvardi Therapeutics, Inc. (“Tvardi”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat fibrosis-driven diseases, today announced that management will deliver a company presentation during the 44th Annual J.P. Morgan Healthcare Conference, being held January 12th […]

-Updated logo and website better reflect patient-centric focus and accessibility as well as new inflection point for company- -ClinNEXUS management will be in attendance during “JPM Week” hosting investor meetings and sharing its new corporate presentation- LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) — ClinNEXUS, (or the “Company”), a data-driven healthcare company that's redefining care

(NASDAQ:TMCI), PONTE VEDRA, Fla., Jan. 08, 2026 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced the successful completion of the first case utilizing its Lapiplasty(R) Lightning(TM) technology. Lightning technology expands

(NASDAQ:CIFR),(NASDAQ:CIFRW), NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ: CIFR) (“Cipher” or the “Company”), a leader in the development of industrial-scale data centers, today announced its participation in several upcoming industry conferences. Cipher's CEO, Tyler Page, may be featured in various discussions highlighting the Company's recent developments and growth strategy. If

(NASDAQ:ICCC), PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell

(NASDAQ:ELDN), Phase 2 BESTOW trial data evaluating tegoprubart in kidney transplantation showed favorable efficacy, safety and tolerability, supporting advancement into Phase 3 development Reported positive preliminary results from first six patients with type 1 diabetes treated with tegoprubart following islet transplantation in UChicago Medicine-led study Tegoprubart continues to be used as key component of immunosuppression

(NASDAQ:TLRY),(TSX:TLRY), International Medical Cannabis Revenue Increases 36%; Canadian Adult-Use Cannabis Revenue Grows 6% Tilray Pharma Achieves Record Quarterly Revenue U.S. Federal Cannabis Rescheduling Expected to Unlock New Market Opportunity for Tilray Medical Expansion into the U.S. Strong Financial Position with $292 Million in Cash and Marketable Securities1 and ~$30 Million Net Cash NEW YORK and

(NASDAQ:PFBC), LOS ANGELES, Jan. 08, 2026 (GLOBE NEWSWIRE) — Preferred Bank (NASDAQ: PFBC), one of the larger independent commercial banks in California, today announced plans to release its financial results for the fourth quarter ended December 31, 2025 before the open of market on Thursday, January 22, 2026. That same day, management will host a

(NASDAQ:ITRI), LIBERTY LAKE, Wash., Jan. 08, 2026 (GLOBE NEWSWIRE) — Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, announced today that it will release financial results for the fourth quarter and full year ended Dec. 31, 2025 at 8:30 a.m. EST on Tuesday, Feb. 17,

(TSX:BOIL),(OTC US:BEOLF),(Other OTC:BEOLF),(Boerse Frankfurt – Freiverkehr:UH9),(Boerse Frankfurt – Freiverkehr:UH9.F),(NYSE:SYY), VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) — Beyond Oil Ltd. (TSX: BOIL) (OTCQB: BEOLF) (“Beyond Oil” or the “Company“), a food-tech innovation company dedicated to reducing health risks associated with fried food while lowering operational costs, minimizing waste and enhancing sustainability, today announced that